[Announcement text for desktop] [Shorter announcement text for mobile] Learn more


"The lesson is not that market corrections are failures. It's that the companies that survive are the ones honest enough to admit when something isn't working and disciplined enough to actually reset."
Tyler Van Horn
Chief Executive Officer, Science 37

Decentralized clinical trials are transforming research by removing geographical barriers, expanding patient access, and making participation more flexible and inclusive.

Rare disease and pediatric clinical trials can place significant burdens on families through travel, caregiving, scheduling challenges, and long-term commitments.

Evidence on direct-to-patient clinical trial models remains limited, although decentralized approaches show promise in improving access, enrollment, efficiency, and convenience.

Science 37 CEO Tyler Van Horn explains how home-based clinical trials improve patient access, simplify participation, and support better retention.